Vericel Co. (NASDAQ:VCEL) Receives $63.14 Average Price Target from Analysts

Shares of Vericel Co. (NASDAQ:VCEL) have received an average rating of “Buy” from the seven research firms that are covering the company, MarketBeat Ratings reports. Seven analysts have rated the stock with a buy rating. The average 12-month price target among brokers that have issued a report on the stock in the last year is $63.14.

VCEL has been the topic of a number of research analyst reports. Stephens restated an “overweight” rating and issued a $65.00 target price on shares of Vericel in a research report on Wednesday, January 15th. StockNews.com cut shares of Vericel from a “hold” rating to a “sell” rating in a research report on Friday. BTIG Research increased their target price on shares of Vericel from $56.00 to $66.00 and gave the stock a “buy” rating in a research note on Tuesday, November 26th. Truist Financial boosted their price target on shares of Vericel from $61.00 to $67.00 and gave the company a “buy” rating in a research note on Wednesday, December 18th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $60.00 price objective on shares of Vericel in a research report on Friday.

Vericel Trading Up 3.4 %

NASDAQ:VCEL opened at $51.29 on Thursday. Vericel has a twelve month low of $39.12 and a twelve month high of $63.00. The company has a market cap of $2.53 billion, a PE ratio of 854.98 and a beta of 1.72. The company’s 50 day moving average is $57.20 and its two-hundred day moving average is $51.83.

Insiders Place Their Bets

In other Vericel news, insider Jonathan Siegal sold 1,092 shares of the company’s stock in a transaction dated Wednesday, February 5th. The stock was sold at an average price of $61.99, for a total transaction of $67,693.08. Following the sale, the insider now owns 1,206 shares in the company, valued at $74,759.94. This represents a 47.52 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Robert L. Md Zerbe sold 2,500 shares of Vericel stock in a transaction dated Wednesday, February 5th. The shares were sold at an average price of $62.50, for a total value of $156,250.00. Following the completion of the transaction, the director now owns 26,595 shares of the company’s stock, valued at $1,662,187.50. The trade was a 8.59 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 20,100 shares of company stock worth $1,206,072 in the last ninety days. 5.20% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Vericel

A number of large investors have recently modified their holdings of VCEL. Wellington Management Group LLP lifted its position in shares of Vericel by 214.0% during the 3rd quarter. Wellington Management Group LLP now owns 587,857 shares of the biotechnology company’s stock worth $24,837,000 after purchasing an additional 400,667 shares during the last quarter. Stifel Financial Corp raised its stake in Vericel by 40.0% in the third quarter. Stifel Financial Corp now owns 28,073 shares of the biotechnology company’s stock valued at $1,186,000 after buying an additional 8,020 shares in the last quarter. Geode Capital Management LLC lifted its holdings in Vericel by 0.8% during the 3rd quarter. Geode Capital Management LLC now owns 1,154,053 shares of the biotechnology company’s stock worth $48,768,000 after buying an additional 9,613 shares during the last quarter. Louisiana State Employees Retirement System boosted its position in shares of Vericel by 0.8% during the 4th quarter. Louisiana State Employees Retirement System now owns 23,900 shares of the biotechnology company’s stock worth $1,312,000 after acquiring an additional 200 shares in the last quarter. Finally, Intech Investment Management LLC purchased a new position in shares of Vericel in the 3rd quarter valued at about $563,000.

About Vericel

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.